证券日报网讯 9月23日晚间，甘李药业发布公告称，近日，公司与FundaçãoOswaldoCruz-Bio- Manguinhos以及BIOMMS.A.（简称"BIOMM"）就巴西生产开发伙伴关系计划项目签订了《技术转移与 供应协议》。同时，公司与BIOMM签订了《供应框架协议》（美元合同）（简称"合同二"），合同二 总金额预计不低于人民币300，000.00万元（含税），最终以实际订单金额为准。上述合同系日常经营 性合同，无需提交公司董事会和股东大会审议。 （编辑 任世碧） ...

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - Gannee Pharmaceutical (603087.SH) has signed a Technical Transfer and Supply Agreement with Funda o Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for a partnership project in Brazil, which is expected to positively impact the company's financial performance in 2025 and beyond [1] Group 1 - The company has entered into a Technical Transfer and Supply Agreement involving the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - A Supply Framework Agreement has also been signed with BIOMM, with a total contract value expected to be no less than RMB 3 billion (including tax), subject to actual order amounts [1] - Both agreements are part of the company's routine business operations and align with its strategic development direction, potentially enhancing overall profitability [1]

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for the Brazil Production Development Partnership (PDP) project, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1 - The company signed a technology transfer and supply agreement involving insulin glargine technology transfer and the supply of active pharmaceutical ingredients and injection solutions [1] - The supply framework agreement with BIOMM is valued at no less than 3 billion RMB (including tax), with the final amount based on actual orders [1] - The contracts are part of the company's routine operations and align with its strategic development direction, potentially enhancing overall profitability [1]

Group 1 - The company, Ganli Pharmaceutical (603087.SH), has signed a "Technology Transfer and Supply Agreement" with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for a partnership project in Brazil [1] - Additionally, the company has entered into a "Supply Framework Agreement" with BIOMM, with a total contract value expected to be no less than 3 billion RMB (including tax), subject to actual order amounts [1]

甘李药业股份有限公司 关于重大合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，甘李药业股份有限公司（以下简称"公司"）与 Fundação Oswaldo Cruz -Bio-Manguinhos（以下简称"FZ"）以及 BIOMM S.A.（以下简称"BIOMM"） 就巴西生产开发伙伴关系计划项目（以下简称"PDP 项目"）签订了《技术转移 与供应协议》（以下简称"合同一"）。同时，公司与 BIOMM 签订了《供应框 架协议》（美元合同）（以下简称"合同二"），合同二总金额预计不低于人民 币 300,000.00 万元（含税），最终以实际订单金额为准。 上述合同系日常经营性合同，公司与交易对方均不存在关联关系，所涉及的 交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。上述合同的签订在公司总经理审批权限范围内，已履行公司内部审批 程序。根据《上海证券交易所股票上市规则》和公司章程规定，上述合同无需提 交公司董事会和股东大会审议。 证券代码：603087 证券简称：甘李药业 公 ...

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its operating performance in 2025 and beyond [1] Group 1: Agreements and Financial Implications - The technology transfer agreement involves the transfer of insulin technology and the supply of active pharmaceutical ingredients and injectable solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount based on actual orders [1] - The signing of these contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Future Impact - The execution of these contracts is anticipated to enhance the company's overall profitability [1] - The agreements are expected to have a positive effect on the company's operating performance in 2025 and subsequent years [1]

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1: Agreements - The technology transfer and supply agreement involves the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount determined by actual order values [1] - The signing of the contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Financial Impact - The execution of these contracts is anticipated to have a positive effect on the company's operating performance in 2025 and subsequent years [1] - The agreements are expected to enhance the overall profitability of the company [1]

Group 1 - A total of 22 companies were investigated by well-known institutions from September 15 to September 22 [1] - The automotive and electronics sectors received the most attention, followed by the biotechnology sector [1] - The company with the highest number of institutional investigations was Hanhigh Group, with 91 institutions participating, followed by World (86 institutions) and Ganli Pharmaceutical (84 institutions) [1] Group 2 - Notable investigations included companies such as Aobi Zhongguang (38 institutions), Welly Transmission (8 institutions), and Changhua Chemical (5 institutions) [2] - Other companies receiving significant attention were Chao Hong Ji (53 institutions), Sanxin Tourism (30 institutions), and Keshun Co. (30 institutions) [2] - Multiple institutions simultaneously investigated Hanhigh Group and Chao Hong Ji, indicating strong interest in these companies [2]

截至6月30日，甘李药业股东户数7.73万，较上期增加3.08%；人均流通股7165股，较上期减少2.99%。 2025年1月-6月，甘李药业实现营业收入20.67亿元，同比增长57.18%；归母净利润6.04亿元，同比增长 101.96%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 机构持仓方面，截止2025年6月30日，甘李药业十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股750.99万股，相比上期增加17.48万股。招商国证生物医药指数A（161726）位居第五大流 通股东，持股580.26万股，相比上期减少24.16万股。南方中证500ETF（510500）位居第六大流通股 东，持股536.87万股，相比上期增加69.27万股。创新药（159992）位居第八大流通股东，持股340.55万 股，为新进股东。南方阿尔法混合A（010357）位居第十大流通股东，持股264.69万股，为新进股东。 华安聚优精选混合（009714）退出十大流通股东之列。 责任编辑：小浪快报 9月23日，甘李药业盘中下跌2.01%，截至10:09，报72.12元/股，成 ...